Pfm Health Sciences, LP Inhibrx, Inc. Transaction History

Pfm Health Sciences, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$32.76 - $39.56 $16.1 Million - $19.4 Million	-490,046 Reduced 91.09%	47,918 $1.68 Million
Q4 2023 Feb 14, 2024	BUY	$14.5 - $38.0 $3.62 Million - $9.48 Million	249,347 Added 86.39%	537,964 $20.4 Million
Q3 2023 Nov 14, 2023	BUY	$15.75 - $26.31 $2.53 Million - $4.23 Million	160,914 Added 126.01%	288,617 $5.3 Million
Q2 2023 Aug 14, 2023	BUY	$16.96 - $27.82 $106,101 - $174,041	6,256 Added 5.15%	127,703 $3.32 Million
Q1 2023 May 15, 2023	BUY	$18.45 - $27.14 $2.24 Million - $3.3 Million	121,447 New	121,447 $2.29 Million

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $550M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

Stay updated on Pfm Health Sciences, LP with notifications on news.